ClinicalTrials.gg

Program

efzimfotase alfa

Its studies are mostly in Hypophosphatasia, led by AstraZeneca.

Furthest: phase 3, since Oct 6, 20233 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
AstraZeneca32 open or runningphase 3since Oct 6, 2023Jul 23, 2021none ahead
  • Named in AstraZeneca’s own pipeline as efzimfotase alfa, phase 4, as of Oct 30, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 23, 2021First study: phase 1 study in HypophosphatasiaFirst studyNCT04980248 · 15 enrolled · United States
  2. Oct 6, 20232 phase 3 studies in HypophosphatasiaNCT06079359, NCT06079281

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06079359Hypophosphatasia · United States, Australia, Belgium and more3Active, not recruitingJan 6, 202630
NCT06079281Hypophosphatasia · United States, Argentina, Australia and more3Active, not recruitingJul 9, 2025124
NCT04980248Hypophosphatasia · United States1CompletedAug 24, 202215

How it is read

Names in the registry

  • “ALXN1850”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.